Savara Revenue and Competitors

Austin, TX USA

Location

$261.1M

Total Funding

Pharma

Industry

Estimated Revenue & Valuation

  • Savara's estimated annual revenue is currently $6.8M per year.(i)
  • Savara received $47.0M in venture funding in October 2017.
  • Savara's estimated revenue per employee is $162,714
  • Savara's total funding is $261.1M.
  • Savara's current valuation is $140.1M. (January 2022)

Employee Data

  • Savara has 42 Employees.(i)
  • Savara grew their employee count by 17% last year.

Savara's People

NameTitleEmail/Phone
1
CFOReveal Email/Phone
2
EVP Global Technical OperationsReveal Email/Phone
3
Head Global Advocacy Relations and Patient EngagementReveal Email/Phone
4
SVP, General CounselReveal Email/Phone
5
Head Clinical OperationsReveal Email/Phone
6
SVP - Head Global Regulatory Affairs and Quality AssuranceReveal Email/Phone
7
EVP Global CommercialReveal Email/Phone
8
SVP Head Clinical ResearchReveal Email/Phone
9
EVP, Global Technical OperationsReveal Email/Phone
10
VP Technical OperationsReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$26.7M13320%N/AN/A
#2
$13.5M676%N/AN/A
#3
$16.1M80-2%N/AN/A
#4
$62.5M0N/AN/AN/A
#5
$10.1M506%N/AN/A
#6
$119.4M59427%N/AN/A
#7
$22.9M1148%N/AN/A
#8
$92.9M4628%N/AN/A
#9
$11.3M56-8%N/AN/A
#10
$7M356%N/AN/A
Add Company

What Is Savara?

Savara Inc. is an orphan lung disease company. Savara's pipeline comprises: Molgradex, an inhaled granulocyte-macrophage colony-stimulating factor, or GM-CSF, in Phase 3 development for PAP, and in Phase 2a development for NTM lung infection; and AeroVanc, a Phase 3 stage inhaled vancomycin for treatment of MRSA infection in cystic fibrosis. Savara's strategy involves expanding its pipeline of potentially best-in-class products through indication expansion, strategic development partnerships and product acquisitions, with the goal of becoming a leading company in its field. Savara's management team has significant experience in orphan drug development and pulmonary medicine, in identifying unmet needs, developing and acquiring new product candidates, and effectively advancing them to approvals and commercialization. More information can be found at www.savarapharma.com. (Twitter: @SavaraPharma)

keywords:Biotechnology,Healthcare,Medical Devices,Pharmaceuticals

$261.1M

Total Funding

42

Number of Employees

$6.8M

Revenue (est)

17%

Employee Growth %

$140.1M

Valuation

N/A

Accelerator

Savara News

2022-04-20 - Savara Announces Debt Refinancing of $26.5M Credit Facility ...

Savara is a clinical stage biopharmaceutical company focused on rare respiratory diseases. Our lead program, molgramostim nebulizer solution, is...

2022-04-06 - Piper Sandler Comments on Savara Inc's Q1 2023 Earnings (NASDAQ:SVRA)

Savara Inc (NASDAQ:SVRA - Get Rating) - Analysts at Piper Sandler issued their Q1 2023 earnings per share estimates for Savara in a research...

2022-03-30 - Savara Reports Fourth Quarter / Year-End 2021 Financial ...

Savara is a clinical stage biopharmaceutical company focused on rare respiratory diseases. Our lead program, molgramostim nebulizer solution, is...

2021-07-01 - Savara : Announces First Patient Dosed in Pivotal Phase 3 Autoimmune Pulmonary Alveolar Proteinosis

AUSTIN, Texas - Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, announced that the first patient has been dosed in the pivotal IMPALA-2 clinical trial. IMPALA-2 is a Phase 3 trial designed to evaluate the efficacy and safety of molgram ...

2021-03-15 - Savara Announces Closing of $130 Million Public Offering Following Full Exercise of Underwriters’ Option

AUSTIN, Texas--(BUSINESS WIRE)--Mar 15, 2021-- Savara Inc. (Nasdaq: SVRA), an orphan lung disease company, today announced the closing of its previously announced underwritten public offering of 57,479,978 shares of its common stock, including 11,694,150 shares sold pursuant to the exercise in ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$4.6M420%$29M
#2
$8.4M42N/AN/A
#3
$8M4214%$14.8M
#4
$4.9M42-5%N/A
#5
$7.9M4217%N/A

Savara Funding

DateAmountRoundLead InvestorsReference
2009-06-11$0.8MAArticle
2012-06-13$8.6MBThe Keiretsu ForumArticle
2013-03-21$16.0MBTech Coast AngelsArticle
2014-06-13$4.5MUndisclosedArticle
2014-10-07$10.0MUndisclosedArticle
2015-12-22$18.5MUndisclosedArticle
2016-03-02$20.0MCArticle
2017-05-02$15.0MUndisclosedSilicon Valley BankArticle
2017-06-05$46.0MUndisclosedJefferies LLCSArticle
2017-10-30$47.0MUndisclosedArticle